Stem cell-based therapy for systemic sclerosis.

IF 2.1 Q3 RHEUMATOLOGY Rheumatology Advances in Practice Pub Date : 2023-11-20 eCollection Date: 2023-01-01 DOI:10.1093/rap/rkad101
Maryam Zare Moghaddam, Mohammad Javad Mousavi, Somayeh Ghotloo
{"title":"Stem cell-based therapy for systemic sclerosis.","authors":"Maryam Zare Moghaddam, Mohammad Javad Mousavi, Somayeh Ghotloo","doi":"10.1093/rap/rkad101","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune diseases, including SSc, are prevalent, affecting autologous connective tissues and caused by the breakdown of self-tolerance mechanisms of the immune system. During the last 2 decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including Parkinson's disease, Alzheimer's disease, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabetes, heart disease, bone disease, renal disease, respiratory disease and haematological abnormalities such as anaemia. This is due to the unique properties of stem cells that both divide and differentiate to the specialized cells in the damaged tissue. Moreover, they impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as SSc. In the present review, the efficacy of stem cell therapy with two main types of stem cells, including mesenchymal stem cells and hematopoietic stem cells, will be reviewed. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell origin, conditioning regimen and complications of stem cell treatment will be discussed.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"7 3","pages":"rkad101"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701795/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkad101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Autoimmune diseases, including SSc, are prevalent, affecting autologous connective tissues and caused by the breakdown of self-tolerance mechanisms of the immune system. During the last 2 decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including Parkinson's disease, Alzheimer's disease, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabetes, heart disease, bone disease, renal disease, respiratory disease and haematological abnormalities such as anaemia. This is due to the unique properties of stem cells that both divide and differentiate to the specialized cells in the damaged tissue. Moreover, they impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as SSc. In the present review, the efficacy of stem cell therapy with two main types of stem cells, including mesenchymal stem cells and hematopoietic stem cells, will be reviewed. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell origin, conditioning regimen and complications of stem cell treatment will be discussed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
以干细胞为基础的系统性硬化症疗法。
自身免疫性疾病,包括SSc,是影响自体结缔组织的流行病,由免疫系统的自我耐受机制崩溃引起。在过去20年里,干细胞疗法越来越多地被认为是各种疾病的治疗选择,包括帕金森病、阿尔茨海默病、中风、脊髓损伤、多发性硬化症、炎症性肠病、肝病、糖尿病、心脏病、骨病、肾病、呼吸系统疾病和贫血等血液异常。这是因为干细胞具有独特的特性,既能分裂,又能分化为受损组织中的特化细胞。此外,干细胞还具有免疫调节特性,可影响免疫异常引起的疾病,如系统性红斑狼疮。在本综述中,将回顾使用间充质干细胞和造血干细胞这两大类干细胞进行干细胞治疗的疗效。此外,还将讨论其他相关问题,包括干细胞治疗的安全性、免疫参数变化、干细胞来源的合适选择、调理方案和并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Rheumatology Advances in Practice
Rheumatology Advances in Practice Medicine-Rheumatology
CiteScore
3.60
自引率
3.20%
发文量
197
审稿时长
11 weeks
期刊最新文献
Challenges in the transition of care for rare connective tissue diseases: results from the 2023 ERN ReCONNET Transition of Care Task Force survey. Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research. Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study. Kawasaki disease preceded by acute appendicitis treated with intravenous immunoglobulin without surgery. Correction to: OA20 Differentiating Lupus Nephritis from Pre-eclampsia-A Diagnostic Dilemma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1